FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of pharmaceutical compositions capable of penetrating one or more biological barriers. Pharmaceutical composition for treating the pulmonary state, wherein the lung condition is selected from asthma, upper and lower airway infections, allergic rhinitis, allergic conjunctivitis, itching and rhinorrhea comprises a combination of therapeutically effective amounts of prodrugs with high permeability and high permeability drugs, and a pharmaceutically acceptable carrier, where said combination, for example, is: hydrochloride of 2-diethylaminoethyl ester of 6-phenoxyacetylacetamidopenicillanic acid, hydrochloride of diethylaminoethylacetylsalcinate, hydrochloride (RS)-N-[1-(1-benzothiene-2-yl)ethyl]-N-(2-diethylaminoacetyloxy)urea, hydrochloride (RS)-5-[1-acetyloxy-2-(isopropylamino)ethyl]benzene-1,3-dioldiacetate and isopropyl-(±)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzolacetate. Also a method for treating a lung condition in a biological subject comprising administering the composition is disclosed.
EFFECT: group of inventions provides compositions that can be effectively delivered to the lungs for their treatment.
3 cl, 30 ex, 60 tbl
